Managers

Bessemer to raise a tenth venture-capital fund

Bessemer Venture Partners has set out to raise a tenth venture-capital fund, according to a filing with the SEC.

Fund Performance: LA Fire and Police pension report, vintages 2016 and 2017

Europe venture capital headed toward record year

Innventure to raise $150 mln maiden venture-capital fund

Innventure has set out to raise a $150 million maiden venture-capital fund, according to a filing with the SEC.

Tot Biopharm attracts $102 mln Series B

Tot Biopharm, a Chinese maker of anti-tumor drugs, has raised $102 million in Series B funding. The investors included China Universal (Cayman) GP Limited, Center Laboratories Group, Vivo Capital, Chengwei Capital, Yuanta Financial Holdings Group and Cathay Capital.

Digital health startup Carepoynt inks $2 mln seed

Carepoynt, a digital health startup, has secured $2 million in seed funding. The investors were not named. US Capital Global provided financial advice to Carepoynt on the transaction.

RiverGlade taps Hudak as operating partner

RiverGlade Capital, a healthcare services-focused private equity firm, has named Jim Hudak as an operating partner. Previously, Hudak was CEO of Paradigm Outcomes.

Astellas buys gene therapy company Quethera

Astellas Pharma has acquired UK-based Quethera, a gene therapy company. According to terms of the deal, Astellas may pay up to 85 million pounds to Quethera shareholders. Quethera was backed by UK Innovation and Science Seed Fund and Cambridge Enterprise.

Artios Pharma nabs $84 mln Series B

UK-based Artios Pharma Limited, a DNA damage response company developing treatments for cancer, has closed $84 million in Series B financing. Andera Partners and LSP led the round with participation from Pfizer Ventures, Novartis Venture Fund, Arix Bioscience, SV Health Investors, M Ventures, IP Group plc and AbbVie Ventures.

Apexigen racks up $73 mln

Apexigen Inc, a biopharmaceutical company, has closed its Series B and Series C funding rounds at a total of $73 million. Decheng Capital led the $15 million Series B round while 3E Bioventures Capital, Virtus Inspire Ventures and SV Tech Ventures led the $58 million Series C round.